Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy
Abstract The Kirsten rat sarcoma (KRAS) oncoprotein has been on drug hunters list for decades now. Initially considered undruggable, recent advances have successfully broken the jinx through covalent inhibition that exploits the mutated cys12 in the switch II binding pocket (KRASG12C). Though this a...
Main Authors: | Abdul Rashid Issahaku, Namutula Mukelabai, Clement Agoni, Mithun Rudrapal, Sahar M. Aldosari, Sami G. Almalki, Johra Khan |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-10-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-22668-1 |
Similar Items
-
KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner
by: Pierre-Antoine Laurent, et al.
Published: (2023-10-01) -
Valorization of Adhatoda vasica leaves: Extraction, in vitro analyses and in silico approaches
by: Mithun Rudrapal, et al.
Published: (2023-03-01) -
1133 Is CSPAMM still needed at 3 T?
by: Croisille Pierre, et al.
Published: (2008-10-01) -
Dual synergistic inhibition of COX and LOX by potential chemicals from Indian daily spices investigated through detailed computational studies
by: Mithun Rudrapal, et al.
Published: (2023-05-01) -
Editorial: Drug repurposing and polypharmacology: A synergistic approach in multi-target based drug discovery
by: Mithun Rudrapal, et al.
Published: (2022-12-01)